Furthermore, the IL-6 knockdown mitigates CRS by reducing pro-inflammatory cytokines such as IL-2, TNF-α, and IFN-γ after T cell reprogramming, thus improving the safety of CAR-T treatments [62]. The gene discussed is IL6; the disease is congenital rubella syndrome.